|
ACO1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.43929354282591E-15 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.4865998149437E-10 |
| Normal-vs-Stage2 |
1.57129999999173E-05 |
| Normal-vs-Stage3 |
2.34739999999123E-05 |
| Normal-vs-Stage4 |
5.445500E-04 |
| Stage1-vs-Stage2 |
1.371190E-01 |
| Stage1-vs-Stage3 |
6.547200E-01 |
| Stage1-vs-Stage4 |
4.233600E-01 |
| Stage2-vs-Stage3 |
8.182000E-02 |
| Stage2-vs-Stage4 |
6.154400E-01 |
| Stage3-vs-Stage4 |
3.353800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.37230268552003E-11 |
| Normal-vs-AfricanAmerican |
7.944600E-03 |
| Normal-vs-Asian |
1.561000E-04 |
| Caucasian-vs-AfricanAmerican |
9.907200E-01 |
| Caucasian-vs-Asian |
6.140200E-01 |
| AfricanAmerican-vs-Asian |
7.051800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.93210000000766E-05 |
| Normal-vs-Female |
1.25455201782643E-14 |
| Male-vs-Female |
2.480000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.99230000006179E-07 |
| Normal-vs-Age(41-60Yrs) |
7.7285999822152E-09 |
| Normal-vs-Age(61-80Yrs) |
6.13480000133393E-08 |
| Normal-vs-Age(81-100Yrs) |
5.950200E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.377400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.181700E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.498400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.516200E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.786200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.940350E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.939600E-01 |
| Classical-VS-Follicular |
6.660500E-02 |
| Classical-VS-Other |
9.955600E-01 |
| Classical-VS-Normal |
8.90376661288883E-12 |
| Tall-VS-Follicular |
8.505600E-02 |
| Tall-VS-Other |
9.000400E-01 |
| Tall-VS-Normal |
2.955000E-03 |
| Follicular-VS-Other |
5.717000E-01 |
| Follicular-VS-Normal |
2.11260000049229E-07 |
| Other-VS-Normal |
2.892800E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.16660039803673E-10 |
| Normal-vs-N1 |
3.000600E-03 |
| N0-vs-N1 |
2.821400E-01 |
|
|
